UWM
MBRX icon

Urban Wealth Management’s Moleculin Biotech MBRX Stock Holding History

Urban Wealth Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$4K Buy
+8
New +$4.65K 0.01% 257

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
JE
JMAC Enterprises Newtown, Pennsylvania $593M AUM 22.22% 1-Year Est. Return

Urban Wealth Management's MBRX Position: Q2 2022 in Review

Urban Wealth Management opened a new position in Moleculin Biotech (MBRX) in Q2 2022: 8 shares worth $4K. The stake represents 0.01% of the portfolio and ranks #257 among its holdings.

23 funds tracked by Wall St. Rank hold MBRX as of Q2 2022.

  • Urban Wealth Management held 8 shares of Moleculin Biotech worth $4K as of Q2 2022.
  • Moleculin Biotech was a new Urban Wealth Management position in Q2 2022.
  • Moleculin Biotech made up 0.01% of Urban Wealth Management's portfolio in Q2 2022, its #257 holding.
  • 23 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2022.

Based on Urban Wealth Management's 13F filing for Q2 2022, filed 22 Jul 2022.